OvaScience Appoints Harald Stock to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScience^SM, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Harald F. Stock, Ph.D., Chief Executive Officer of the Grünenthal Group, to its Board of Directors.

“I look forward to helping OvaScience bring these new potential therapies to patients throughout the world.”

“Harald joins our Board at a time when OvaScience continues to achieve its goals towards developing new infertility treatments for the U.S. market, while evaluating multiple commercial opportunities outside the U.S.,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “The global fertility market is nearly 10 times larger than the U.S. alone, and growing rapidly. Harald’s expertise and success commercializing products in global healthcare markets will be important to OvaScience as we advance our ex-U.S. strategy.”

Since 2009, Mr. Stock has served as Chief Executive Officer of the Grünenthal Group, an international research-based pharmaceutical company headquartered in Germany. Prior to joining Grünenthal, he was Chairman and Managing Director of the German DePuy Group, the Orthopaedics Division of Johnson & Johnson. Previously, he held various positions of increasing responsibilities in local and global functions and corporate divisions of the Roche Group until 2005, when he was appointed Senior Vice President of the Global Near Patient Testing business based in Graz, Austria. Mr. Stock is a Board Member at the European Federation of Pharmaceutical Industries and Associations (efpia) and immatics biotechnologies GmbH. He also previously served as Vice-Chairman of the Supervisory Board of PAION AG, was Board Observer of ConforMIS, Inc. and represented Johnson & Johnson on the Board of BVMed, the German Medical Technology Industry Association. Mr. Stock holds a Ph.D. in inorganic chemistry from the University of Heidelberg.

“OvaScience’s unique approach to developing treatments for infertility may offer new solutions to address the increasing rate of female infertility in the U.S. and abroad,” said Mr. Stock. “I look forward to helping OvaScience bring these new potential therapies to patients throughout the world.”

About OvaScience

OvaScience (OTC: OVSC) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPC^SM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT^SM aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com.

Forward-Looking Statements

Any statements in this press release about OvaScience’s strategy, future plans, prospects and future expectations constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. OvaScience anticipates that subsequent events and developments will cause its views to change. While OvaScience may elect to update these forward-looking statements in the future, it specifically disclaims any obligation to do so.